REYKJAVIK, Iceland, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s facility in Iceland by the U.S.

Marketing authorization issued in European Economic Area for Uzpruvo ® , the first biosimilar to Stelara ® , a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves way for biosimilar competition in the approximately €2.5 billion (US$2.7 billion) EU ustekinumab

The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea ® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular Degeneration (AMD) REYKJAVIK, Iceland, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global

The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint REYKJAVIK, Iceland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and

Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022 Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara ® (ustekinumab) The European Medicines Agency proposed market

REYKJAVIK, ICELAND, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2023, after U.S.

Pr Jamte ki TM is the second biosimilar developed under th is partnership that receives market ing authorization in Ca nada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatology Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity